智通财经APP讯,复星医药(600196.SH)发布公告,近日,公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(合称“复宏汉霖”)自主研发的HLX109注射液(即靶向IL1RAP的单克隆抗体)用于泛发性脓疱型银屑病治疗的I期临床试验方案获相关人类研究伦理委员会批准、并通过澳大利亚药品管理局备案,系该药品于全球范围内取得的首个临床试验许可。复宏汉霖拟于条件具备后于澳大利亚开展该药品的相关临床研究。
智通财经APP讯,复星医药(600196.SH)发布公告,近日,公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(合称“复宏汉霖”)自主研发的HLX109注射液(即靶向IL1RAP的单克隆抗体)用于泛发性脓疱型银屑病治疗的I期临床试验方案获相关人类研究伦理委员会批准、并通过澳大利亚药品管理局备案,系该药品于全球范围内取得的首个临床试验许可。复宏汉霖拟于条件具备后于澳大利亚开展该药品的相关临床研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.